Breaking News Instant updates and real-time market news.

AMGN

Amgen

$167.34

0.53 (0.32%)

08:54
10/04/16
10/04
08:54
10/04/16
08:54

Amgen, Nuevolution announce strategic collaboration in oncology, neuroscience

Nuevolution AB announced that Amgen and Nuevolution have entered into a multiple target research collaboration to develop and commercialize novel therapeutics in the areas of oncology and neuroscience. Nuevolution will apply its Chemetics drug discovery platform to discover and advance potential therapeutics of interest to Amgen. The research collaboration brings together Nuevolution's proprietary drug discovery platform with Amgen's disease expertise and drug development capabilities. Under the terms of the agreement, Amgen has an exclusive option to obtain all rights to successfully developed programs. Nuevolution is eligible to receive a license fee payment upon option exercise and milestone payments upon achievement of specified research, development and commercial milestones, amounting up to $410M per target. Nuevolution would also be entitled to receive royalties on future sales. Additional financial details are not being disclosed. Nuevolution will be responsible for the early research phase and Amgen will work collaboratively with Nuevolution during late-stage research. Amgen will be fully responsible for preclinical development, clinical development and commercialization worldwide.

  • 07

    Oct

  • 05

    Nov

  • 06

    Nov

  • 19

    Jul

AMGN Amgen
$167.34

0.53 (0.32%)

09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.
09/27/16
PIPR
09/27/16
NO CHANGE
PIPR
Overweight
Amgen's Kyprolis in good shape despite trial miss, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Amgen's Kyprolis is still likely to be viewed as a "potent backbone, with the right drugs" after a Phase 3 study in front-line myeloma failed to reach its primary endpoint. The analyst believes the impact of the failed trial on Kyprolis use will be limited and he reiterates an Overweight rating on Amgen.
09/27/16
GSCO
09/27/16
NO CHANGE
Target $206
GSCO
Conviction Buy
Goldman surprised by Amgen's Kyprolis outcome in first-line multiple myeloma
Last night, Amgen announced Phase 3 Kypolis CLARION study did not meet the primary endpoint in first-line multiple myeloma. Goldman analyst Terence Flynn was surprised by this outcome given the prior positive superiority data for Kyprolis versus Velcade in the Phase III ENDEAVOR trial. Flynn sees risk to his Kyprolis $1B sales estimate in a first-line setting, but awaits for additional details from the call and further information regarding another ongoing Phase III trial. He expects Amgen shares to be weak on the news but said the company has additional drivers beyond Kyprolis including Repatha for high cholesterol and Erenumab for migraine with additional data expected in 2H 2016 and Q1 2017. Flynn remains Conviction Buy rated on Amgen and maintains his $206 price target.
09/01/16
09/01/16
NO CHANGE

Amgen's sBLA for Blincyto approved by FDA
Amgen's supplemental Biologics License Application for Blincyto has been approved by the FDA to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL. Blincyto was granted breakthrough therapy, priority review and orphan drug designations by FDA, and is now approved in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL. In November 2015, BLINCYTO was granted conditional marketing authorization in the European Union for the treatment of adults with Ph- relapsed or refractory B-cell precursor ALL.

TODAY'S FREE FLY STORIES

CNX

CONSOL

$21.30

-0.48 (-2.20%)

, CNNX

CONE Midstream

$21.33

-0.15 (-0.70%)

15:02
12/10/16
12/10
15:02
12/10/16
15:02
Conference/Events
CONE Midstream participates in an analyst and investor day »

Management participates…

CNX

CONSOL

$21.30

-0.48 (-2.20%)

CNNX

CONE Midstream

$21.33

-0.15 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CNNX

CONE Midstream

$21.33

-0.15 (-0.70%)

, CNX

CONSOL

$21.30

-0.48 (-2.20%)

14:59
12/10/16
12/10
14:59
12/10/16
14:59
Conference/Events
CONSOL to host analyst and investor day »

Analyst and Investor Day…

CNNX

CONE Midstream

$21.33

-0.15 (-0.70%)

CNX

CONSOL

$21.30

-0.48 (-2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BG

Bunge

$73.36

-0.04 (-0.05%)

14:54
12/10/16
12/10
14:54
12/10/16
14:54
Conference/Events
Bunge to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

14:50
12/10/16
12/10
14:50
12/10/16
14:50
Conference/Events
AMD to host Summit Ridge a "Zen"-based CPU at New Horizon »

President & CEO Su…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$50.76

0.61 (1.22%)

14:41
12/10/16
12/10
14:41
12/10/16
14:41
Conference/Events
Arthur J. Gallagher to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

NYT

New York Times

$14.10

0.15 (1.08%)

14:34
12/10/16
12/10
14:34
12/10/16
14:34
Conference/Events
Detroit Economic Club to hold a luncheon meeting »

Mark Thompson, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$27.16

0.89 (3.39%)

14:28
12/10/16
12/10
14:28
12/10/16
14:28
Conference/Events
AstraZeneca has a luncheon meeting with Philadelphia Securities Association »

Luncheon Meeting being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 16

    Feb

CASC

Cascadian Therapeutics

$5.65

-0.03 (-0.53%)

, GHDX

Genomic Health

$30.81

-0.17 (-0.55%)

04:55
12/10/16
12/10
04:55
12/10/16
04:55
Conference/Events
UT Health Science Center to hold a symposium »

2016 San Antonio Breast…

CASC

Cascadian Therapeutics

$5.65

-0.03 (-0.53%)

GHDX

Genomic Health

$30.81

-0.17 (-0.55%)

MYGN

Myriad Genetics

$17.40

0.41 (2.41%)

RDUS

Radius Health

$43.94

-3.13 (-6.65%)

OCX

OncoCyte

$6.15

0.05 (0.82%)

ABBV

AbbVie

$61.54

0.64 (1.05%)

BAYRY

Bayer

$100.04

1.14 (1.15%)

CELG

Celgene

$113.47

0.41 (0.36%)

CLDX

Celldex

$3.75

0.01 (0.27%)

DNA

Bought by RHHBY

HRTX

Heron Therapeutics

$14.90

-0.55 (-3.56%)

PFE

Pfizer

$31.70

0.76 (2.46%)

PBYI

Puma Biotechnology

$36.50

0.05 (0.14%)

TSRO

TESARO

$129.97

-1.57 (-1.19%)

NSTG

NanoString

$21.79

-0.35 (-1.58%)

NVS

Novartis

$69.74

2.15 (3.18%)

NVTA

Invitae

$7.24

0.28 (4.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 11

    Jan

BBSI

Barrett Business

$62.30

1.85 (3.06%)

, BREW

Craft Brew

$16.65

0.45 (2.78%)

04:55
12/10/16
12/10
04:55
12/10/16
04:55
Conference/Events
Roth Capital to hold a conference »

5th Annual ROTH Utah…

BBSI

Barrett Business

$62.30

1.85 (3.06%)

BREW

Craft Brew

$16.65

0.45 (2.78%)

CHKE

Cherokee

$11.10

-0.35 (-3.06%)

DFBG

Differential Brands

$3.20

0.25 (8.47%)

DLA

Delta Apparel

$20.77

-0.39 (-1.84%)

ESCA

Escalade

$13.65

-0.15 (-1.09%)

FLKS

Flex Pharma

$6.29

-0.01 (-0.16%)

KONA

Kona Grill

$12.75

0.05 (0.39%)

LNDC

Landec

$15.05

-0.25 (-1.63%)

MEET

MeetMe

$5.63

0.16 (2.93%)

MITK

Mitek Systems

$6.50

0.35 (5.69%)

MB

MINDBODY

$20.70

-0.25 (-1.19%)

OSIS

OSI Systems

$78.17

1.22 (1.59%)

PLNT

Planet Fitness

$21.01

-0.07 (-0.33%)

ROX

Castle Brands

$0.75

0.0309 (4.30%)

PRTS

U.S. Auto Parts

$3.33

0.09 (2.78%)

RSYS

RadiSys

$4.77

0.11 (2.36%)

SWHC

Smith & Wesson

$21.07

-0.16 (-0.75%)

VSTO

Vista Outdoor

$38.62

-1.24 (-3.11%)

WMAR

West Marine

$9.41

0.13 (1.40%)

ZAGG

ZAGG

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 13

    Dec

  • 09

    Jan

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

, CSCO

Cisco

$30.06

0.11 (0.37%)

18:32
12/09/16
12/09
18:32
12/09/16
18:32
Hot Stocks
Arista Networks favored in ITC initial determination on four of six patents »

Arista Networks (ANET)…

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

CSCO

Cisco

$30.06

0.11 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

TKTDY

Takata Corporation

$10.70

0.05 (0.47%)

18:22
12/09/16
12/09
18:22
12/09/16
18:22
Periodicals
U.S. DOT looks to accelerate pace of Takata air bag replacements, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DV

DeVry

$31.90

0.9 (2.90%)

18:17
12/09/16
12/09
18:17
12/09/16
18:17
Hot Stocks
Breaking Hot Stocks news story on DeVry »

International Value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

18:10
12/09/16
12/09
18:10
12/09/16
18:10
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Cornerstone OnDemand has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.12

-0.0014 (-1.17%)

18:03
12/09/16
12/09
18:03
12/09/16
18:03
Hot Stocks
NYSE MKT says CEL-SCI noncompliant with certain listing requirements »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$89.00

0.68 (0.77%)

18:01
12/09/16
12/09
18:01
12/09/16
18:01
Periodicals
Exxon CEO Tillerson emerges as top candidate for secretary of state, WSJ says »

Exxon Mobil CEO Rex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

17:58
12/09/16
12/09
17:58
12/09/16
17:58
Hot Stocks
H.B. Fuller announces restructuring, to eliminate, relocate 220 positions »

H.B. Fuller has announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$287.77

-1.77 (-0.61%)

17:53
12/09/16
12/09
17:53
12/09/16
17:53
Periodicals
Biogen looks like a bargain, Barron's reports »

Biogen trades at just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$40.40

0.63 (1.58%)

17:42
12/09/16
12/09
17:42
12/09/16
17:42
Periodicals
Sanofi to lay off 20% of U.S. diabetes, cardiovascular staff, Bloomberg says »

The layoffs include parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

17:38
12/09/16
12/09
17:38
12/09/16
17:38
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Investor Praesidium said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TACO

Del Taco

$14.75

-0.39 (-2.58%)

17:34
12/09/16
12/09
17:34
12/09/16
17:34
Hot Stocks
Breaking Hot Stocks news story on Del Taco »

PW Acquisitions cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

  • 09

    Dec

UNVR

Univar

$26.36

0.54 (2.09%)

, BXLT

Baxalta

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Univar names Eric Foster chief information officer »

Univar (UNVR) named Eric…

UNVR

Univar

$26.36

0.54 (2.09%)

BXLT

Baxalta

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Breaking Hot Stocks news story on Parnell 

Parnell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$20.81

0.2 (0.97%)

, NVRO

Nevro

$76.38

-1.88 (-2.40%)

17:24
12/09/16
12/09
17:24
12/09/16
17:24
Hot Stocks
Boston Scientific files patent infringement suit against Nevro »

Nevro (NVRO) announced…

BSX

Boston Scientific

$20.81

0.2 (0.97%)

NVRO

Nevro

$76.38

-1.88 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RTN

Raytheon

$146.30

0.14 (0.10%)

17:21
12/09/16
12/09
17:21
12/09/16
17:21
Hot Stocks
Raytheon awarded $101.9M government contract »

Raytheon Co., Goleta,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$8.77

-0.16 (-1.79%)

17:18
12/09/16
12/09
17:18
12/09/16
17:18
Hot Stocks
CEMEX receives subpoena from SEC regarding Foreign Corrupt Practices Act »

On December 9, 2016,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.